Plegridy approved for relapsing remitting MS in England
NICE has published its final decision recommending that Plegridy can be prescribed by the NHS for relapsing remitting MS.
In May 2018, NICE carried out a review of several of the MS drugs and decided that Avonex, Extavia, Rebif, Copaxone and Brabio should continue to be available on the NHS in England. At the time, NICE was unable to make a recommendation on Plegridy and has now completed a separate appraisal.
The MS Trust contributed throughout the process.
We are pleased that NICE has approved Plegridy for people with relapsing remitting MS. We were able to make a strong case to NICE thanks to those of you who told us about your experiences of taking this treatment and the importance of having a greater choice of disease modifying drugs.
- David Martin, Chief Executive Officer, MS Trust
Plegridy (peginterferon beta 1a) is a disease modifying drug for relapsing remitting MS which you inject once a fortnight. Plegridy is already approved for use in Scotland and Wales.
Find out more about Plegridy.
Find out more
- NICE decision
- Plegridy
- Disease modifying drugs
- MS Decisions - find out about disease modifying drugs for relapsing MS
Covid-19 vaccines and MS
12 Nov 2020 - 00:00
We speak to a neurologist about whether a future Covid-19 vaccine would be safe and effective for people with MS.
A round-up of research from MS Virtual 2020
4 Nov 2020 - 00:00
An update from the this ECTRIMS and ACTRIMS which is the largest annual MS research conference.
Siponimod (Mayzent) approved for active secondary progressive MS in England and Wales
15 Oct 2020 - 00:00
The MS Trust is delighted that siponimod (Mayzent) has also been approved by NICE in England and Wales.
MS in the Media
27 Nov 2020 - 00:00
- Depression affects multitasking in MS
- Benefits process in Scotland
- Cancer risks and multiple sclerosis
- Gut immune cells and relapses
MS in the Media
20 Nov 2020 - 00:00
- New study for advanced MS
- Campaign for fair benefits during the pandemic
- Stem cells compared to Lemtrada
- DMD use and finances
David Martin appointed Chair of the Neurological Alliance
18 Nov 2020 - 00:00
The MS Trust is delighted to announce that CEO David Martin, has been voted in as Chair of the Neurological Alliance.
Sign up to our emails
Get the latest news and research sent straight to your inbox. Find out first about the latest developments in MS treatments, plus updates on the work of the MS Trust.
Share
